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2Abstract
Glucagon-like peptide 1 (GLP-1) mimetics are effective drugs for treatment of type 2 diabetes, and there is 
consequently extensive interest in increasing endogenous GLP-1 secretion and L-cell abundance. Here we 
identify G protein-coupled bile acid receptor 1 (GPBAR1) as a selective regulator of intestinal L-cell 
differentiation. Lithocholic acid and the synthetic GPBAR1 agonist: L3740 selectively increased L-cell 
density in mouse and human intestinal organoids and elevated GLP-1 secretory capacity. L3740 induced 
expression of Gcg and transcription factors Ngn3 and NeuroD1. L3740 also increased the L-cell number, GLP-
1 levels and improved glucose tolerance in vivo. Further mechanistic examination revealed that the effect of 
L-3740 on L-cells required intact GLP-1 receptor and serotonin 5-HT4 receptor signaling. Importantly, 
serotonin signaling through 5-HT4 mimicked the effects of L3740, acting downstream of GLP-1. Thus, 
GPBAR1 agonists and other powerful GLP-1 secretagogues facilitate L-cell differentiation through a 
paracrine GLP-1-dependent and serotonin-mediated mechanism. 
Keywords: bile acids, intestinal organoids, GLP-1, serotonin, L-cells, enterochromaffin cells
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3Introduction
Synthetic glucagon-like peptide 1 (GLP-1) analogues and dipeptidyl peptidase 4 (DPP-4) inhibitors today 
constitute effective components of type 2 diabetes treatment. Both strategies potentiate the action of the GLP-1 
system, leading to beneficial effects on insulin and glucagon secretion, food intake and nutrient metabolism. 
Consequently, increasing the number of intestinal endocrine L-cells, the main source of GLP-1, represent an 
attractive alternative strategy for augmenting GLP-1 bioavailability (1-3). 
Differentiation of L-cells is a continuous process in the intestine. Constantly renewing intestinal epithelium 
has the capacity to expand the population of L-cells if the appropriate signals are present (4). In the crypts of 
the intestine, stem cells expressing Lgr5 give rise to proliferating transit amplifying cells. Each one of these 
cells can become a secretory cell progenitor expressing a specific lineage marker Math1, or an absorptive cell 
progenitor labeled by Hes1 expression - a process controlled by Notch signaling. Next, some of these secretory 
cell progenitors start expressing Ngn3, which defines endocrine progenitors (5). At the next stage, new 
transcription factors direct the maturation towards a certain hormonal cell type (6), where NeuroD1, Arx, Foxa 
1 and Foxa 2 are associated with differentiation into L-cells (7-9). In addition to GLP-1, L-cells secrete other 
hormones important for metabolic regulation, such as cholecystokinine (CCK), neurotensin (NTS) and peptide 
YY (PYY). Somatostatin (SST) secreting cells and serotonin (5-HT) secreting cells, which constitute the 
majority of enteroendocrine cell population, develop as mostly separate branches.
We have previously shown that differentiation of L-cells can be pharmacologically increased in vitro and in 
vivo by a Notch inhibitor (1) and Ras homologue family member A-associated coiled-coil-containing protein 
kinases (ROCK) inhibitor (3), through a general increase in the proportion of secretory cells. The subsequent 
increase in L-cell number resulted in amplified GLP-1 secretion, which augmented insulin responses and 
restored glucose tolerance in a mouse model of type 2 diabetes (1, 3). However, the therapeutic potential of 
Notch and ROCK inhibitors used to manipulate L cell differentiation is limited due to adverse effects during 
chronic application of these drugs as their effects are not selective to the L-cell lineage. On the other hand, 
short chain fatty acids (SCFAs), endogenous products of intestinal microbiota metabolism, selectively 
enhance differentiation and consequently the number of L-cells (9, 10). SCFAs are also effective GLP-1 
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4secretagogues (11) and thus we hypothesized that locally amplified GLP-1 secretion drives L-cell 
differentiation. Among other natural GLP-1 secretagogues, secondary bile acids, synthesized by intestinal 
microflora from primary bile acids, are powerful stimulants of GLP-1 release through activation of the G 
protein-coupled bile acid receptor 1 (GPBAR1) (12-14). Lithocholic acid (LCA) has the highest affinity to 
GPBAR1 among secondary bile acids (13). In humans, plasma concentrations of bile acids are at low 
micromolar range (15). Intracellularly, GPBAR1 activates the Gs signaling pathway resulting in increased 
cAMP, which is particularly effective in stimulating release of GLP-1 (16) and other co-expressed peptide 
hormones from the L-cell, including PYY and neurotensin (17). Therefore, synthetic GPBAR1 agonists are 
promising drug candidates acting locally in the intestine, to enhance GLP-1 secretion (18). In this study, the 
effect of GPBAR1 activation on L-cell number, GLP-1 secretion and gene expression of L-cell lineage 
markers was tested in the small intestine organoid platform. The observed positive effect of GPBAR1 agonists 
on L-cell differentiation was dependent on GLP-1 signaling and, surprisingly, mimicked by downstream 
serotonin signaling conceivably through paracrine stimulation from neighboring enterochromaffin cells (19).  
Research design and methods
Animals
Non-fasted male GLU-Venus mice with transgenic expression of yellow fluorescent protein (YFP) in L-cells 
(20), GPBAR1 knockout mice (12), their wild type littermates and GLP1R knockout mice (21) bred on 
C57BL/6J background were used for organoids studies at the age of 6 - 8-month and GLU-Venus female mice 
were used for in vivo testing at the age of 3 – 4 months. Mice of different age were used to reduce costs for 
mouse colony maintenance. We did not expect a difference in the mechanisms of intestinal cell differentiation 
in 3-8 month-old mice, or significant differences between males and females. To our experience, organoids 
from 3 or 8 months old males and females show similar characteristics. In all experiments, littermates from 
the same cage were used as controls. C57BL/6 were purchased from Charles River. All animal experiments 
were approved by the Danish Animal Inspectorate (2018-15-0201-01424). 
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5Human intestinal samples
Human jejunum fragments were obtained from Roux-en-Y gastric bypass operations from 4 patients with no 
anti-cancer treatment (Sydvestjysk Hospital, Esbjerg, Denmark). All patients participated with informed 
consent, with the research protocol approved by the National Research Ethics Committee (H-18015120). 
Mouse and human organoid culture and experiment design
Mice were sacrificed by cervical dislocation. Small intestine crypts were isolated from the ileum by EDTA 
incubation (22) and seeded in Matrigel in advanced Dulbecco’s modified Eagle’s medium/F12 containing 100 
units/mL penicillin/streptomycin, 10 mmol/L HEPES, 2 mmol/L Glutamax, supplements N2 and B27, 50 
ng/mL murine epidermal growth factor (all from Life Technologies), 1 mmol/L N-acetylcysteine (Sigma-
Aldrich), 100 ng/ml murine Noggin and 500 ng/ml murine R-spondin-1 (Peprotech). For maintenance, 
organoids were split every 4-6 days and cultured in 48-well plates. Test compounds were added into the culture 
medium and the organoids were analysed after 48 h. By the time of the readout, the majority of organoids had 
3-5 crypts. Duodenal organoids were generated and analyzed the same way. Human organoid lines were 
generated and cultured as described (23). The experiments were performed after the first passage.
LCA (Sigma Aldrich), L3740 (Merck-TGR5-A, ref. 17), tropisetron, RS-39604, BIMU 8 (all from Tocris), 
GPR40 agonist AM-1638 (24) and GPR119 agonist AR53 (AR231453, ref. 16, 24) were first dissolved in 
DMSO as 1mM stock, and diluted with the culture medium to 10, 20 or 50 µM for LCA and 1 µM for other 
compounds. DMSO (0.01%) was added to control wells. After 48 hours, the organoids were collected for 
qPCR analysis or fixed in 4% paraformaldehyde for GLP-1 immunostaining (for human, GPBAR1 KO, wild 
type and GLP-1R KO mouse organoids) (10) and microscopy analysis. The experiment was performed 3-6 
times in duplicates using organoids from 6 mice. The L-cell percentage in organoids was assessed in 
wholemount preparation from a 3D stack of 10-µm-thick digital sections, each containing 3-8 organoids, 
acquired on a Zeiss confocal microscope (LSM 780) at 20X magnification using Zen Software. Label-positive 
cells from each image were manually counted and expressed as percentage of cells calculated from nuclear 
labeling with DAPI, analyzed with Image J software. Number of measurements is presented in Figure legends. 
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6GLP-1 secretion measurements
Organoids cultured in 96 well plates for 48 hours were washed 3 times in Advanced DMEM/F12 with Hepes 
and L-glutamine. Medium with stimulants (L3740, LCA or BIMU 8) and control medium (without stimuli) 
was added to the wells with 5 replicates for each condition (unless otherwise indicated), and slowly shaken 
on an orbital shaker after addition of the medium and before the collection. After 2 hours at 37°C, the medium 
was collected and assayed for GLP-1 content using GLP-1 V-plex MSD kit (Mesoscale). For glucose 
stimulation, the organoids were washed and pre-incubated with DMEM supplemented with 2% FBS 
containing no glucose and glutamine for 1 hour. Then DMEM containing 18 mM glucose and 2 mM L-
glutamine or DMEM with no stimulants (control) was added.  Experiment was performed 3-4 times. The 
values were normalized to the DNA content in the wells measured with DNA quantification kit (Sigma).
qPCR
Total RNA was extracted from organoids using mini RNA extraction kit (Qiagen). cDNA was synthesized 
using Superscript III kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). Quantitative real-time 
PCR was performed on a real-time PCR System (Bio-Rad) using SYBR green assays. We used Beta 2 
microglobulin (B2M) as endogenous control gene (10). Mouse and human primer sequences were described 
earlier (3, 10) and for Gpbar1, 5Htr3a, 5Htr3b and 5Htr4 are presented in Table 1. Each gene expression 
was tested in 2-4 organoid lines from different mice generating 2-4 templates from each line from different 
passages (biological replicates, n) in independent experiments. The individual measurements were averaged 
from duplicated qPCR wells (technical replicates). 
In-feed GPBAR1 agonist treatment 
Two groups of Glu-Venus mice were fed regular feed ground into powder during 4 days before the experiment. 
The body weight was monitored for potential weight losses due to the feed change. Mice with stable body 
weight were randomized so that one group received L3740-containing feed during 3 days, and the other 
continued with the same powder feed (control). Assuming that mice consumed at least 2.8 g of feed during 24 
hours (25), the mice received 60mg/kg of body weight of the compound per day (0.64 mg of L3740 per 1 g of 
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7mouse feed). The mice were fasted for 5 hours before the oral glucose tolerance test. Glucose (2g/kg of body 
weight) was given as oral gavage and blood samples were taken before and 15, 30, 60 and 120 minutes after 
the bolus. For plasma GLP-1 measurements, about 50 µL of blood was collected from retroorbital sinus from 
a separate cohort of L3740-treated and control mice before (0 min) and 10 minutes after the glucose bolus. 
The total GLP-1 Meso Scale Discovery assay (cat. No. K150JVC-4) was used for determination of plasma 
GLP-1 concentrations. Mice were euthanized and fragments of ileum 2 cm from caecum were collected and 
fixed in 4% PFA. The percentage of YFP-positive cells was calculated in 6-8 transverse cryosections per 
mouse as described above. Blood glucose was measured with a Contour-Next Bayer Glucometer. Area under 
the curve with baseline subtraction was calculated for glucose dynamics using GraphPad Prism 8.
In situ hybridization 
Adult C57BL/6 male mice were euthanized by cervical dislocation, fragments of intestine were excised, rinsed 
and fixated by flushing with Bouin’s fixative (50% ethanol and 5% acetic acid in dH2O). Hereafter, the 
intestines were cut open and rolled onto a toothpick to create so called “Swiss rolls”. “Rolls” were fixated 24 
hours in 4% paraformaldehyde and subsequently embedded in paraffin. In situ hybridization was performed 
on 5-µm sections using RNAscope® Multiplex Fluorescent Assay (ACDbio) with the probes for Htr4 (Mm-
Htr4, # 408241), Htr3a (Mm-Htr3a, #411141), Lgr5 (Mm-LGR5-C3, #312171-C3), Math1 (Mm-Atoh1-C3, 
#408791-C3), CD133 (Mm-Prom1-C3, #412221-C3), and Ngn3 (Mm-Neurog3-C2, #422401-C2)  following 
manufactures instruction. Htr4, CD133 and Ngn3 were applied as a triple labeling. Images of staining were 
acquired on LSM 780 using Zen Software.  
Statistics 
Quantitative results are presented as mean values with SEM. Comparison of 2 groups was done using 
nonpaired 2-tailed Student’s t-test, assuming normality of data. qPCR data were analyzed using Wilcoxon 
matched-pairs signed rank test for data from different organoid lines. P values less than 0.05 were 
considered significant (* < 0.05; ** <0.01; *** < 0.001). Data involving more than 2 groups were assessed 
by ANOVA with Bonferroni post-hoc test (GraphPad Prism 8).
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8Results 
Activation of GPBAR1 increases L-cell number in intestinal organoids
To investigate whether GPBAR1 activation could increase L-cell number we applied LCA to organoids 
generated from GLU-Venus mouse ileum crypts, where L-cells are labeled by transgenic YFP expression (20). 
Addition of 10 μM LCA to the culture medium for 48 h increased the L-cell number 2-fold (Figure 1A-B). 
Increasing the LCA concentration did not increase L-cell number further (Figure S1A-B), however, 20 and 50 
μM LCA impaired crypt formation in organoids indicating toxicity, which was not observed with application 
of 10 μM LCA (Figure S1A). To avoid potential non-specific effects we used a potent, synthetic, non-
detergent GPBAR1 agonist L3740 (17, Figure S1C). Incubation with 1 μM L3740 increased the number of L-
cells by 2.5 fold within 48 hours (Figure 1C-D), while maintaining normal morphology of the organoids (data 
not shown). Immunostaining for GLP-1 confirmed that YFP positive cells produced GLP-1 (Figure S1D). L-
cells were mostly localized to the crypt domains in both control and L3740-treated groups. We have also tested 
the effect of L3740 on L-cell numbers in duodenal organoids and found a 1.7-fold increase in the L-cell 
percentage in the treated group compared to the control (Figure S1E). 
Next, we tested GLP-1 secretion from GPBAR1-treated organoids in response to a combination of natural 
stimulants of GLP-1 release – glucose and L-glutamine, and observed a 1.8-fold increase in the secretory 
capacity of the cultures compared with the control (Figure 1E), which is in agreement with the observed 
increase in L-cell number.
qRT-PCR analysis of specific cell markers was used as an indirect measure of representation of different cell 
types. We found increased expression of Gcg and Cck transcripts in L3740-treated organoids, but not of other 
L-cell hormones such as Pyy and Nts (Figure 1F). We tested the expression of Tph1, a marker of serotonin-
secreting enterochromaffin cells and found no difference between the control and treated group. Because the 
Tph1 gene encodes a key enzyme for serotonin synthesis and not the final product, we also determined the 
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9enterochromaffin cell representation and found no changes after the treatment with L3740 (Figure S1F).   
Levels of mRNA transcripts encoding the transcription factors NeuroD1 and Ngn3 associated with L-cell 
endocrine specification was also elevated, whereas expression of Arx, Foxa1 and Foxa2 remained un-changed 
(Figure 1G). Expression of secretory cell progenitor markers Math1 and Dll1 did not change, indicating that 
the increase in L-cell number was modulated after the Notch-mediated secretory cell specification (26). 
Accordingly, the expression of Hes-1, a marker of progenitor of non-secretory absorptive cells, enterocytes, 
was the same in control and L3740 group. No changes in the expression levels of I-fabp and Itf (enterocyte 
and goblet cell markers, respectively) were observed and the expression of Lyz1, a Paneth cell marker, was 
slightly reduced (Figure 1G). The expression of Lgr5, a stem cell marker, was unchanged (Figure 1G). 
To directly test whether GPBAR1 is required for bile-acid induced L-cell differentiation we generated 
organoids from GPBAR1 knockout mice and their wild type littermates. Exposure to L3740 did not affect the 
number of L-cells (Figure 1H) nor the expression of Gcg, Nd1 and Ngn3 (Figure 1I) in the absence of 
functional GPBAR1 signaling. Consistent with these findings, L3740 and LCA did not induce GLP-1 
secretion from organoids lacking GPBAR1 (Figure 1J). Thus, both LCA and L3740 selectively induced L-
cell differentiation, through mechanisms requiring functional GPBAR1 signaling.
L3740 increases L-cell numbers in vivo 
To investigate whether GPBAR1 stimulation can amplify L-cell numbers in vivo, L3740 was administered in-
feed to GLU-Venus mice for 3 days. L3740-treated mice showed a modest increase in glucose tolerance after 
an oral glucose challenge (Figure 2A-B) and elevated basal GLP-1 plasma levels (0 min) and 10 minutes after 
the gavage (Figure 2C). Body weight in the control and treated group before and after the treatment was the 
same (Figure S1G). There was no difference in feed intake between the groups (2.6 ± 0.1 vs 2.7± 0.1 
g/mouse/day, control and treated group, respectively, NS). L-cell number in the distal ileum was increased 
(Figure 2D-E) and accompanied by elevated expression of Gcg and Ngn3 compared with controls (Figure 2F). 
This indicates that the GPBAR1 agonist L3740 stimulates formation of new endocrine-committed intestinal 
cells in vivo in mice. 
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GPBAR1 stimulation increases L-cell abundance in human organoids
We next investigated the effect of GPBAR1 activation in human intestinal epithelium. Human ileal organoids 
were treated with 1 μM L3740 for 48 hours. Human organoid culture requires addition of Wnt3A and MAPK 
inhibitors, which interfere with normal cell differentiation, and the percentage of mature cells in human 
organoids consequently is much lower than in an intact intestine or in mouse organoids (23). In mouse 
organoids, L-cell were usually found in crypt domains, while in human organoids we did not observe a clear 
pattern for L-cell location (Figure 3B). GPBAR1 stimulation induced a 1.6-fold increase in the L-cell number 
compared with control cells, i.e. similar to what was observed in the murine organoids (Figure 3A). Vehicle-
stimulated organoids only contained L-cells in 48 % of organoids, and the majority of those had only one or 
two L-cells regardless of the organoid size (Figure 3B). After L3740 treatment, L-cells were observed in 71 
% of organoids (Figure 3C). Considering the irregular scattering of L-cells, we compared the frequency 
distribution of L-cells in organoid population. A shift towards more cells per organoid was detected in L3740-
treated group (Figure 3C). The expression of GCG was increased in L3740-treated group, as well as expression 
of NEUROD1, but we did not detect changes in NGN3 expression, probably because the overall expression 
of NGN3 was surprisingly low in the human organoids (Figure 3D). These data indicate that L3740 stimulates 
L-cell development also in human intestinal epithelium. 
GPBAR1 induction of L-cell differentiation requires intact GLP-1 signaling 
We hypothesized that activation of GPBAR1 promotes L-cell differentiation by chronically increasing 
secretion of GLP-1. To test this, the effect of L3740 was probed in intestinal organoids from GLP-1 receptor 
deficient mice (GLP1RKO, ref. 21). The increase in L-cell number determined by immunostaining was 
completely eliminated in the absence of functional GLP-1 receptor signaling (Figure 4A). This indicates that 
the effect of GPBAR1 activation requires the endogenous GLP-1 receptor and that L-cell number is regulated 
by a positive feedforward mechanism. 
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In an attempt to maximize the proposed effect of GLP-1 receptor activation, we used 100 μM liraglutide, a 
synthetic GLP-1 analogue, in the organoid culture medium and assessed the L-cell number. Liraglutide 
increased the number of L-cells (Figure S2A), but it is difficult to interpret this effect because the peptide also 
had a pronounced stimulatory effect on organoid growth (Figure S2B). 
GLP-1 secretagogues induce L-cell differentiation through a paracrine cross-talk with serotonin 
signaling
In the intestinal epithelium, the GLP-1 receptor is almost exclusively and highly expressed by the large 
population of enterochromaffin cells producing serotonin, or 5-hydroxytryptamine (5-HT) (19). Thus, we 
hypothesized that differentiation of L-cells could be mediated through serotonin release. We stimulated L-cell 
differentiation in mouse organoids with L3740 in the presence of two different serotonin receptor inhibitors – 
tropisetron, a prototype rather broad-spectrum serotonin antagonist blocking 5-HTR3 and 5-HTR4 (26), and 
5-HTR4 blocker RS-39604. Both drugs abolished L3740-induced L-cell differentiation (Figure 4B). In situ 
hybridization demonstrated that the Htr4 is expressed in a majority of epithelial cells of the small intestinal 
crypts (Figure 4C) and Htr3, as expected (27, 28),  is expressed mainly in submucosal ganglia (Figure 4C). In 
view of these facts and because 5-HTR4 inhibition was sufficient to inhibit the effect of L3740, we focused 
on the 5-HT4 receptor. Correspondingly, we found that L3740 treatment increased the expression of Ht4r in 
the organoids (Figure 4D). To determine which differentiating cells in the crypt express Htr4, we performed 
in situ hybridization co-staining for Htr4 and stem cell marker Lgr5, transit-amplifying cell marker CD133, 
secretory progenitor marker Math1 and endocrine progenitor marker Ngn3. We found that Htr4 was present 
in all these cell types (Figure 4E). This is in accordance with the capacity of these cells to differentiate into L-
cells, which supports our discovery of a role for serotonin in regulating the number of L-cells. 
 Next, we incubated organoids with the 5-HTR4 agonist BIMU 8 alone and in combination with L3740. BIMU 
8 produced a similar increase in the number of L-cells as L3740 and combination of the two did not result in 
an additive or synergistic effect (Figure 4F). Importantly, BIMU 8 had no acute effect on GLP-1 release 
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(Figure S2C). When tested in GLP1RKO mouse organoids and GPBAR1KO mouse organoids, BIMU 8 still 
increased the number of L-cells (Figure 4G and 4H), further supporting that the increase in L-cell numbers by 
L3740 was an indirect effect mediated by activation of serotonin receptors. 
Based on the key role of GLP-1 signaling in the effect of GPBAR1 activation on L-cell differentiation, we 
tested other efficient L-cell secretagogues: a synthetic agonist of free fatty receptor 1 (FFA1 or GPR40), AM-
1638, and a lipid amide receptor GPR119 agonist, AR53. These two secretagogues were tested alone, or in 
combination with the 5-HTR4 antagonist. Both agents alone robustly increased the number of L-cells in 
organoids to a similar degree as L3740 (Figure 4I), while inhibiting 5HTR4 abolished the effect of both the 
FFAR1 agonist and the GPR119 agonist (Figure 4I). Thus, these findings indicate that serotonin signaling acts 
downstream of GLP-1 receptor signaling, enabling regulation of intestinal cell differentiation into L-cells.  
Discussion
Based on studies on secondary bile acids produced by intestinal microbiota, we here propose a general 
mechanism, through which GLP-1 secretagogues stimulate L-cell differentiation and thereby increase L-cell 
number in the intestinal epithelium. This mechanism involves paracrine GLP-1 stimulation of serotonin 
secretion and downstream activation of serotonin receptors conceivably on progenitor cells in the intestinal 
crypts (Figure S3). Activation of GPBAR1 increased L-cell differentiation in human and mouse intestinal 
organoids, supported by increased expression of transcription factors guiding L-cell differentiation. 
Interestingly, the GPBAR1 agonist L3740 only increased the expression of Gcg and Cck (which is known to 
be produced by L-cells to some degree), but not PYY and Nts, which are expressed in certain populations of 
L-cells, and these results may reflect the prolonged maturation time for these populations (17). As a large 
fraction of enteroendocrine cell subsets express Gcg (29), GPBAR1 activation can further stimulate Gcg 
expression and prohormone convertase 1/3 (30), thereby converting more cells into GLP-1 producing cells. 
Thus, GBPAR1 modulates L-cell differentiation selectively in contrast to earlier methods to increase the 
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number of L-cells (1-3). Using GPBAR1-deficient mouse organoids we demonstrate that the effect indeed 
was specific for GPBAR1 when L3740 was applied. However, other efficient GLP-1 secretagogues acting on 
FFAR1 (GPR40) and GPR119 mimicked the effect of L3740 on the L-cell number. This is likely due to high 
enrichment of GPBAR1, FFAR1 and GPR119 (20) in L-cells and the ability of L-cells to secrete large amounts 
of GLP-1 upon its Gs activation. Previously, similar effects on L-cell abundance have been shown for FFAR2 
and FFAR3, receptors for other microbial metabolites, short chain fatty acids (10). 
GLP-1 receptor has been implicated in cell proliferation and differentiation (31). As data from GLP1R-
deficient mice indicate, GLP-1 receptor signaling specifically regulates L-cell differentiation. GLP-1 receptor 
is mainly expressed within intestinal intraepithelial lymphocytes, enteric neurons, and enterochromaffin cells 
in the intestinal epithelium and GLP-1 stimulates release of serotonin (19). The role of serotonin in growth 
and maturation of intestine has previously been described, although these effects were attributed to the 
interaction of enterochromaffin cells with enteric neurons (32, 33). Here we show that 5-HTR4 is 
predominantly expressed in the crypt, in stem cells, supporting earlier data (34), but also in secretory and 
endocrine progenitor cells. Importantly, serotonin receptor antagonist abolished the increase in L-cell number 
induced by GLP-1 secretagogues. In agreement, activation of serotonin signaling increased L-cell number 
regardless of the presence of GPBAR1 and GLP-1 receptor, indicating that serotonin acts downstream of GLP-
1. 
GPBAR1 agonist L3740 stimulated formation of new endocrine-committed intestinal cells in vivo in mice. 
The increased glucose tolerance and GLP-1 levels in L3740-treated mice, indicates that the increase in L-cell 
abundance was physiologically significant. It is possible that positive influence of bile acids on energy 
expenditure and improved glucose metabolism (35) are partially caused by increased L-cell numbers. Together 
with our data from human organoids, this suggests that GPBAR1 may be a potential therapeutic target for 
increase endogenous GLP-1 production in humans with type 2 diabetes. The current limitation of use of 
GPBAR1 agonists as antidiabetic agents is gall bladder dysfunction (18, 36). However, altering the intestinal 
microbiota in favor of microorganisms producing bile acids (37-39) to activate GPBAR1 locally appears to 
be an intriguing possibility. 
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In conclusion, bile acids may act as regulators of L-cell number in the intestinal epithelium. Here we show a 
specific target, GPBAR1, which increases the differentiation into L-cells but does not alter other cell ratios in 
intestinal epithelium. We propose a model whereby GLP-1 levels contribute to control of L cell abundance 
through serotonin signaling, explaining the ability of the body to adjust the L-cell numbers to compensate for 
changes in nutrient availability. Finally, our study demonstrates that a directing the differentiation in the 
intestinal epithelium into specific cell types is possible and GPBAR1 (and possibly other GPCRs) could be a 
target for modulation of L-cell number as a therapeutic strategy against type 2 diabetes. 
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LEGENDS
Figure 1. Activation of GPBAR1 by the bile acid LCA and a synthetic agonist increases L-cell number 
in organoids. (A) Representative images of control and organoids treated with 20 µM LCA. L-cells are 
labeled by Gcg-YFP expression in this and following images unless otherwise indicated. Nuclei labeled by 
DAPI. Bar 50 μm. (B) L-cell numbers in control organoids (n = 70) and organoids treated with LCA (n = 78). 
In this and following figures data are mean ± SEM (unless otherwise indicated). * p < 0.05, ** p < 0.01, ** p 
< 0.001.  (C) Representative images of control and L3740-treated organoids. Bar 50 μm. (D) L-cell numbers 
in control (n = 38) and L3740-treated organoids (n = 30). (E) GLP-1 secretion from L3740-treated organoids 
stimulated by 18 mM glucose and 2 mM L-glutamine. Data from 3 experiments performed with 5 replicas. 
(F) Gene expression of intestinal hormones in L3740-treated organoids (n = 4 - 10 in each series). (G) Gene 
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expression of intestinal cell type markers and transcription factors directing L cell development. Lgr5 and 
CD133 – proliferating cells, ITF – goblet cells, Lyz1 – Paneth cells, I-Fabp – enterocytes; Ngn3,  NeuroD1, 
Arx, Foxa1/2 – L-cell transcription factors (n = 4-10 experiments in each series). (H) L-cell numbers, identified 
by immunostaining, in control and GPBAR1KO and wild type mouse organoids after 48-h-treatment with 
L3740 (n = 21-25). (I) Expression of L-cell differentiation markers in control and L3740-treated GPBAR1 
knockout organoids. n = 3 for each series. (G) GLP-1 release in response to LCA and L3740 in GPBAR1 
knockout organoids. n = 5 for each series.
Figure 2. In-feed L3740 treatment increases oral glucose tolerance, GLP-1 secretion and L-cell number 
in mice. (A) Plasma glucose excursion during an oral glucose tolerance test after 5 hour fasting and. L3740, 
black squares; control (vehicle), white squares. n = 10 for each series. (B) Area under the curve from data in 
panel A (AUC). (C) Plasma GLP-1 concentrations in control and L3740-treated mice and 10 minutes after 
glucose. n = 8 for each series. (B) L-cells (Gcg-YFP) in the ileum of control and L3740 treated mice. Nuclei 
labeled by DAPI. Bar 50 μm. (C) L-cell percentage in mouse ileum sections. n = 4 for each series. (D) 
Expression of Gcg and Ngn3 (n = 4 for each series).
Figure 3. GPBAR1 stimulation increases L-cell abundance in human organoids. (A) L-cell numbers in 
control (n = 66) and L3740-treated human small intestine organoids (n = 44). (B) Representative images of 
control and L3740-treated human organoids. L-cells are labeled by GLP-1 immunostaining (white arrows), 
nuclei labeled by DAPI. Bar 50 µm. (C) A shift in the organoid distribution by the cell number after treatment 
with L3740. Percentages of organoids with various L-cell numbers are presented from data in panel A. p < 
0.05 by Chi-Square contingency test.  (D) Expression of NGN3, NEUROD1 (ND1) and GCG (n = 4 for each 
series, generated from 2 human organoid lines).
Figure 4. GPBAR1 induction of L-cell differentiation requires cross-talk with serotonin signaling. (A) 
Effect of L3740 in GLP1RKO mouse organoids. n = 47 for control and n = 58 for L3740-treated series. (B) 
Effect of 5-HTR3 and 5-HTR4 inhibitor tropisetron (TRP) and 5-HTR4 inhibitor RS-39604 in organoids alone 
and in combination with L3740. (C) Htr4 and Htr3 in mouse ileum identified by in situ hybridization. Nucleus 
labeling by DAPI (blue). White arrows indicate positive Htr3 staining outside of the epithelial layer. Bar 50 
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µm. (D) L3740 increases Htr4 expression in organoids. n = 7 for control and n = 6 for L3740-treated series. 
(E) Co-expression of Htr4 and cell markers Lgr5, CD133, Math1 and Ngn3 in mouse ileal crypts identified 
by in situ hybridization. White arrows indicate positive Htr4 staining. Nuclei are labeled with DAPI (blue). 
Bar 20 µm. (F) Effect of 5-HT4R agonist BIMU 8 and L3740 on the L-cell number. n = 17-35 in panels A 
and B. (G) BIMU 8 increases L-cell number in GLP1R KO mouse organoids, while L3740 has no effect on 
the L-cells. n = 47 for control and n = 20 for L3740-treated series. (H) BIMU8 increases L-cell numbers in 
GPBAR1KO mouse organoids. n = 21 for control and n = 23 for L-3740-treated series. (I) FFAR1 agonist 
AM-1638 and GPR119 agonist AR53 have a similar effect on the number of L-cells, while addition of RS-
39604 counteracts this effect, n = 33 – 42.
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Table S1. Quantitative RT-PCR primers. Related to Methods. Mouse primers were generated using Primer 
3 software. Relative expression values were derived using delta delta CT method with beta-2-microglobulin 
(B2M) as an endogenous reference.
Gene Alias Forward Reverse
G-protein-
coupled bile 
acid receptor
Gpbar1 CCC CAA CTT TTG TTT CCT TTC 
C
GGC TGC AAC ACT GCC ATG 
TA
5-hydroxy
tryptamine 
receptor 3A
5Htr3a AAATCAGGGCGAGTGGGAGCTG GACACGATGATGAGGAAGA
CTG
5-hydroxy-
tryptamine 
receptor 3b
5Htr3b CTGCATGGCCCTCTTGGTT AATCTAGACTCCTCGGCATC
5-hydroxy
tryptamine 
receptor 4
5Htr4 AGTTCCAACGAGGGTTTCAGG CAGCAGGTTGCCCAAGATG
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Figure S1. Related to Figure 1. (A) Dose-response to LCA. N = 19-44 images per series, each containing 1-6 
organoids. (B) Representative images from the dose-response experiment: toxic effects of increasing LCA 
concentrations on organoid morphology. Bar 50 μm. (C) Co-localization of GLP-1 staining and Gcg-YFP 
expression. Bar 50 μm. (E) L-cell numbers in duodenum organoids treated with L3740. n = 41 for control 
and n = 33 for treated series. (F) Enterochromaffin cell numbers in ileum organoids treated with L3740. n = 
28 for control and n = 32 for treated series. (G) Body weight in mice before and after treatment with L3740. 
n = 10. Data are mean ± SEM (unless otherwise indicated). * p < 0.05, ** p < 0.01, ** p < 0.001. 
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Figure S2. Related to Figure 4. (A) Effect of1 μM liraglutide on the L-cell number. N = 23 for each series. 
(B) Images of control and liraglutide-treated organoids. Bar 200 μm.  (C) GLP-1 secretion from organoids in 
response to BIMU-8. L-3740 was used as positive control. N = 3 for each series with 2-3 replicates. Data are 
mean ± SEM (unless otherwise indicated). * p < 0.05, ** p < 0.01, ** p < 0.001.
Page 28 of 29
For Peer Review Only
Diabetes
Figure S3. Related to Figure 4. Schematic illustration of the proposed mechanism by which activation of 
GPBAR1 by bile acids increases the number of L-cells in the intestine. Bile acids induce release of GLP-1, 
which activates enterochomaffin cells (EC). Serotonin, released from ECs, acts on endocrine cell progenitors 
resulting in increased L-cell numbers.
Page 29 of 29
For Peer Review Only
Diabetes
